Switch theme
Sign up to access all valuation multiples
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
2011
157
LTM Revenue $5.7M
LTM EBITDA -$88.5M
$328M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Absci has a last 12-month revenue (LTM) of $5.7M and a last 12-month EBITDA of -$88.5M.
In the most recent fiscal year, Absci achieved revenue of $4.5M and an EBITDA of -$89.1M.
Absci expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Absci valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.7M | XXX | $4.5M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$88.5M | XXX | -$89.1M | XXX | XXX | XXX |
| EBITDA Margin | -1561% | XXX | -1965% | XXX | XXX | XXX |
| EBIT | -$110M | XXX | -$109M | XXX | XXX | XXX |
| EBIT Margin | -1943% | XXX | -2402% | XXX | XXX | XXX |
| Net Profit | -$106M | XXX | -$103M | XXX | XXX | XXX |
| Net Margin | -1876% | XXX | -2274% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Absci's stock price is $3.
Absci has current market cap of $438M, and EV of $328M.
See Absci trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $328M | $438M | XXX | XXX | XXX | XXX | $-0.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Absci has market cap of $438M and EV of $328M.
Absci's trades at 72.4x EV/Revenue multiple, and -3.7x EV/EBITDA.
Equity research analysts estimate Absci's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Absci has a P/E ratio of -4.1x.
See valuation multiples for Absci and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $438M | XXX | $438M | XXX | XXX | XXX |
| EV (current) | $328M | XXX | $328M | XXX | XXX | XXX |
| EV/Revenue | 57.9x | XXX | 72.4x | XXX | XXX | XXX |
| EV/EBITDA | -3.7x | XXX | -3.7x | XXX | XXX | XXX |
| EV/EBIT | -3.0x | XXX | -3.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.1x | XXX | -4.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbsci's last 12 month revenue growth is 246%
Absci's revenue per employee in the last FY averaged $29K, while opex per employee averaged $0.7M for the same period.
Absci's rule of 40 is -1423% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Absci's rule of X is -945% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Absci and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 246% | XXX | 147% | XXX | XXX | XXX |
| EBITDA Margin | -1561% | XXX | -1965% | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1423% | XXX | -1719% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -945% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $29K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1408% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2502% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| NetraMark | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Bullfrog AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Immuneering | XXX | XXX | XXX | XXX | XXX | XXX |
| Personalis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Absci acquired XXX companies to date.
Last acquisition by Absci was XXXXXXXX, XXXXX XXXXX XXXXXX . Absci acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Absci founded? | Absci was founded in 2011. |
| Where is Absci headquartered? | Absci is headquartered in United States of America. |
| How many employees does Absci have? | As of today, Absci has 157 employees. |
| Who is the CEO of Absci? | Absci's CEO is Mr. Sean McClain. |
| Is Absci publicy listed? | Yes, Absci is a public company listed on NAS. |
| What is the stock symbol of Absci? | Absci trades under ABSI ticker. |
| When did Absci go public? | Absci went public in 2021. |
| Who are competitors of Absci? | Similar companies to Absci include e.g. NetraMark, SyntekaBio, Bullfrog AI, Immuneering. |
| What is the current market cap of Absci? | Absci's current market cap is $438M |
| What is the current revenue of Absci? | Absci's last 12 months revenue is $5.7M. |
| What is the current revenue growth of Absci? | Absci revenue growth (NTM/LTM) is 246%. |
| What is the current EV/Revenue multiple of Absci? | Current revenue multiple of Absci is 57.9x. |
| Is Absci profitable? | Yes, Absci is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Absci? | Absci's last 12 months EBITDA is -$88.5M. |
| What is Absci's EBITDA margin? | Absci's last 12 months EBITDA margin is -1561%. |
| What is the current EV/EBITDA multiple of Absci? | Current EBITDA multiple of Absci is -3.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
